Compare Dolby Laboratories, Inc. (DLB) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Invesco Ltd. — how do they compare? Dolby Laboratories, Inc. trades at $58.74 (market cap $5.47B), while Invesco Ltd. trades at $29.51 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 2.4× Dolby Laboratories, Inc.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Invesco Ltd. for 77 Days on average.
| DLB | IVZ | |
|---|---|---|
Market Cap | $5.47B | $13.28B |
Volume | 1,058,284 | 3,698,033 |
Sector | Technology | Financials |
52-Week High | $69.58 | $33.31 |
52-Week Low | $48.51 | $22.44 |
Typical Hold Time | 98 Days | 77 Days |
Enterprise Value | $4.85B | $23.45B |
Dividend Yield | 2.46% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.45, showing modest daily gains of 0.17%. The stock faces bearish technical signals with resistance at $59 and support at $58. Fundamentally, DLB maintains strong profitability with 87.61% gross margins and has beaten earnings estimates in three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB presents a mixed outlook with analyst consensus pointing to significant upside (target $90.33) despite near-term execution risks. The company's strong cash position and expanding digital content partnerships provide growth catalysts, though licensing volatility and competitive pressures remain key challenges for investors.
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.
The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
